Johnson & Johnson MedTech recently launched their Cereglide 92 catheter system for the treatment of acute ischemic stroke.

The challenges of translating neuroprotective interventions with promising efficacy in animal studies into effective treatments for patients with stroke are well documented, with issues including ...

Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery ...

In a randomized clinical trial, giving the clot-busting medication alteplase up to 24 hours after stroke symptoms first appeared increased the odds of better recovery by 50% compared to those who ...

Intensive BP lowering after successful endovascular thrombectomy for acute anterior circulation ischemic stroke did not improve 90-day functional outcomes vs. standard BP control, a speaker ...

(Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first ...

Removing a clot blocking a medium- or small-sized artery in the brain mechanically is a safe treatment for a common type of ...

University of Cincinnati experts will present research at the International Stroke Conference 2025 in Los Angeles.

“Poststroke rehabilitation requires an interdisciplinary, holistic approach to the management, treatment, and rehabilitation of stroke sequelae, with the patient and caregivers as vital members of the ...